Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Mar 8;114(3):475-476.
doi: 10.1093/jnci/djab159.

RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer

Ashley M Hopkins  1 , Ganessan Kichenadasse  1   2 , Jessica M Logan  3 , Andrew Rowland  1 , Michael J Sorich  1
Affiliations
Editorial

RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer

Ashley M Hopkins et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Comment in

  • Response to Hopkins, Kichenadasse, Logan, et al.
    Wang X, Ricciuti B, Alessi JV, Nguyen T, Awad MM, Lin X, Johnson BE, Christiani DC. Wang X, et al. J Natl Cancer Inst. 2022 Mar 8;114(3):477-478. doi: 10.1093/jnci/djab161. J Natl Cancer Inst. 2022. PMID: 34450659 Free PMC article. No abstract available.

Comment on

References

    1. Wang X, Ricciuti B, Alessi JV, et al.Smoking history as a potential predictor of immune checkpoint inhibitor efficacy in metastatic non-small cell lung cancer. J Natl Cancer Inst. 2021;113(12):1761–1769. - PMC - PubMed
    1. Ballman KV. Biomarker: predictive or prognostic? J Clin Oncol. 2015;33(33):3968–3971. - PubMed
    1. Mo J, Hu X, Gu L, et al.Smokers or non-smokers: Who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. World J Surg Oncol. 2020;18(1):15. - PMC - PubMed
    1. Dai L, Jin B, Liu T, et al.The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: a systematic review and meta-analysis. EClinicalMedicine. 2021;38:100990. doi:10.1016/j.eclinm.2021.100990. - PMC - PubMed
    1. Hopkins AM, Rowland A, Kichenadasse G, et al.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer. 2017;117(7):913–920. - PMC - PubMed

MeSH terms

Substances